ArticleMethods in enzymology2025
The direct expression of apo heme proteins: A general strategy to obtain designer heme proteins with abiological cofactors.
Article in Methods in enzymology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Substituting the porphyrin cofactor in heme proteins with non-iron porphyrins or related tetrapyrrole macrocycles provides one strategy to obtain new functional proteins. This approach commonly relies on the removal of heme from the native holoprotein under harsh, denaturing conditions, which is not suitable for all proteins. To circumvent this limitation, the RP523 strain of E. coli can be utilized for the expression-based incorporation of abiological cofactors by leveraging the unique heme permeability of this strain's cell wall. However, not all synthetic analogs are able to traverse the RP523 cell wall. Here, we report the direct expression of apo heme proteins, which can then be reconstituted with the desired cofactor, thereby expanding the utility of the RP523 approach. As a test case, we describe the incorporation of zinc protoporphyrin IX (PPIX) into the heme nitric oxide/oxygen binding protein (H-NOX) from Caldanaerobacter subterraneus (Cs) and the heme acquisition system protein A (HasA) from Pseudomonas aeruginosa (Pa). Since the optical properties of the cofactor are sensitive to subtle differences in the protein environment, we compare the absorption and emission spectroscopy of these conjugates. It was found that higher cofactor incorporation was achieved by reconstitution. However, higher quantum yields were observed for samples prepared by expression-based methods, suggesting greater fidelity in cofactor binding. Our method for the direct expression of apo heme proteins substantially reduces the required amount of the cofactor and represents a generalizable approach for the incorporation of porphyrin analogs into heme proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.